Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Cadrenal Therapeutics  / Equity Bottom-Up

<ul><li>On March 4, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced a collaboration agreement with Abbott to support the company's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.</li><li>The collaboration calls for Abbott to share insights from recent HeartMate 3 trials while also assisting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3 expertise.</li><li>Having the support of Abbott will be a huge advantage for Cadrenal and should ensure that the TECH-LVAD trial is performed with the maximum efficiency as Abbott has a tremendous amount of experience working with this patient population.</li></ul>

On March 4, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced a collaboration agreement with Abbott to support the company's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.The collaboration calls for Abbott to share insights from recent HeartMate 3 trials while also assisting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3 expertise.Having the support of Abbott will be a huge advantage for Cadrenal and should ensure that the TECH-LVAD trial is performed with the maximum efficiency as Abbott has a tremendous amount of experience working with this patient population.

CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial 